The cost of visual impairment: Purposes, perspectives, and guidance

Investigative Ophthalmology and Visual Science

Volumn 51, Issue 4, 2010, Pages 1801-1805

  Frick, Kevin D ^a   Kymes, Steven M ^b   Lee, Paul P ^c   Matchar, David B ^d   Lynne Pezzullo, M ^e   Rein, David B ^f   Taylor, Hugh R ^g  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DUKE UNIVERSITY EYE CENTER   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Research Triangle Park ^*  (Australia)

^f RTI INTERNATIONAL   (United States)

^g UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; ECONOMIC EVALUATION; GOVERNMENT; HEALTH CARE COST; HEALTH CARE SYSTEM; HOSPITALIZATION COST; HUMAN; INCIDENCE; INCOME; MEDICAL SOCIETY; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RETINA MACULA AGE RELATED DEGENERATION; RISK FACTOR; VISUAL IMPAIRMENT; WELLBEING; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; COST; COST OF ILLNESS; ECONOMICS; HOSPITALIZATION; PATIENT; SOCIOECONOMICS; VISUAL DISORDER;

COST OF ILLNESS; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; HEALTH CARE COSTS; HEALTH EXPENDITURES; HUMANS; INCIDENCE; PREVALENCE; SEVERITY OF ILLNESS INDEX; VALUE OF LIFE; VISION DISORDERS; VISUALLY IMPAIRED PERSONS;

EID: 77951232399     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.09-4469     Document Type: Article

References (22)

1. Taylor HR, Pezzullo ML, Keeffe JE. The economic impact and cost of visual impairment in Australia. Br J Ophthalmol. 2006;90(3):272-275.
2. Frick KD, Gower EW, Kempen JH, Wolff JL. Economic impact of visual impairment and blindness in the United States. Arch Ophthalmol. 2007;125(4):544-550.
3. Rein DB, Zhang P, Wirth KE, et al. The economic burden of major adult visual disorders in the United States. Arch Ophthalmol. 2006;124(12):1754-1760.
4. Frick KD, Foster A. The magnitude and cost of global blindness: an increasing problem that can be alleviated. Am J Ophthalmol. 2003;135(4):471-476.
5. Javitt JC, Zhou Z, Willke RJ. Association between vision loss and higher medical care costs in Medicare beneficiaries costs are greater for those with progressive vision loss. Ophthalmology. 2007;114(2):238-245.
6. Shamanna BR, Dandona L, Rao GN. Economic burden of blindness in India. Indian J Ophthalmol. 1998;46(3):169-172.
7. Smith TS, Frick KD, Holden BA, Fricke TR, Naidoo KS. Potential lost productivity resulting from the global burden of uncorrected refractive error. Bull World Health Organ. 2009;87(6):431-437.
8. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press: 1996.
9. Tarn TYH, Dix Smith M. Pharmacoeconomic guidelines around the world. ISPOR Connections. 2004;10(4):5-15.
10. Tan-Torres Edejer T, Baltussen R, Adam T, et al., eds. Making Choices in Health: WHO Guide to Cost-Effectiveness Analysis. Geneva: World Health Organization; 2003.
11. Rice DP. Cost of illness studies: what is good about them? Inj Prev. 2000;6(3):177-179.
12. Keefe JE. Costs of vision impairment: present and future issues. Expert Rev Pharmacoeconomics Outcomes Res. 2007;7(5):523-527.
13. Wong EY, Chou SL, Lamoureux EL, Keeffe JE. Personal costs of visual impairment by different eye diseases and severity of visual loss. Ophthalmic Epidemiol. 2008;15(5):339-344.
14. Brouwer WB, Koopmanschap MA, Rutten FF. Productivity costs in cost-effectiveness analysis: numerator or denominator: a further discussion. Health Econ. 1997;6(5):511-514.
15. Rothermich EA, Pathak DS. Productivity-cost controversies in costeffectiveness analysis: review and research agenda. Clin Ther. 1999;21(1):255-267.
16. Access Economics. Clear insight: the economic impact and cost of vision loss in Australia. Melbourne: Eye Research Australia; 2004. Available at http://www.cera.org.au/publications/reports/access/clearinsight_overview.pdf. Accessed March 3, 2010.
17. Boardman AE, Greenberg DH, Vining AR, Weimer DL. Cost-Benefit Analysis: Concepts and Practice. Upper Saddle River, NJ: Prentice Hall; 1996.
18. Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making. 2000;20(3):332-342.
19. Mason H, Jones-Lee M, Donaldson C. Modelling the monetary value of a QALY: a new approach based on UK data. Health Econ. 2009;18(8):933-950.
20. Appleby J, Devlin N, Parkin D, Buxton M, Chalkidou K. Searching for cost effectiveness thresholds in the NHS. Health Policy. 2009; 91(3):239-245.
21. Braithwaite RS, Meltzer DO, King JT Jr, Leslie D, Roberts MS. What does the value of modern medicine say about the $50,000 per qualityadjusted life-year decision rule? Med Care. 2008;46(4):349-356.
22. WHO Commission on Macroeconomics and Health. Macroeconomics and health: investing in health for economic development. Report of the Commission on Macroeconomics and Health. Geneva: World Health Organization: Geneva; 2001